tiprankstipranks
Biogen Inc. (BIIB)
NASDAQ:BIIB
US Market
BIIB
Biogen
RESEARCH TOOLSreports
Want to see BIIB full AI Analyst Report?

Biogen (BIIB) Stock Forecast & Price Target

5,048 Followers
See the Price Targets and Ratings of:

BIIB Analyst Ratings

Moderate Buy
28Ratings
Moderate Buy
18 Buy
9 Hold
1 Sell
Based on 28 analysts giving stock ratings to
Biogen
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BIIB Stock 12 Month Forecast

Average Price Target

$222.67
▲(25.55% Upside)
Based on 28 Wall Street analysts offering 12 month price targets for Biogen in the last 3 months. The average price target is $222.67 with a high forecast of $260.00 and a low forecast of $157.00. The average price target represents a 25.55% change from the last price of $177.35.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"129":"$129","162":"$162","195":"$195","228":"$228","261":"$261"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$260.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":222.66666666666666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$222.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":157,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$157.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[129,162,195,228,261],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,209.74,213.60615384615386,217.4723076923077,221.33846153846156,225.20461538461538,229.07076923076923,232.93692307692308,236.80307692307693,240.66923076923078,244.5353846153846,248.40153846153845,252.2676923076923,256.13384615384615,{"y":260,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,209.74,210.73435897435897,211.72871794871796,212.72307692307692,213.7174358974359,214.71179487179487,215.70615384615385,216.7005128205128,217.6948717948718,218.68923076923076,219.68358974358975,220.6779487179487,221.6723076923077,{"y":222.66666666666666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,209.74,205.68307692307692,201.62615384615384,197.56923076923078,193.5123076923077,189.45538461538462,185.39846153846153,181.34153846153845,177.2846153846154,173.2276923076923,169.17076923076922,165.11384615384617,161.05692307692306,{"y":157,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":130.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":131.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.22,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":179.09,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":183.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.23,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.74,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$260.00Average Price Target$222.67Lowest Price Target$157.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on BIIB
Jason Zemansky
Bank of America Securities
Bank of America Securities
$217
Hold
22.36%
Upside
Reiterated
07/17/26
Biogen Maintained at Hold as Analyst Keeps $217 Price Target Amid Alzheimer’s Pipeline Uncertainty
Wells Fargo Analyst forecast on BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
40.96%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (NASDAQ: FTH), Oncology Institute (NASDAQ: TOI) and Biogen (NASDAQ: BIIB)
Piper Sandler Analyst forecast on BIIB
David Amsellem
Piper Sandler
Piper Sandler
$225
Buy
26.87%
Upside
Reiterated
07/15/26
Piper Sandler Remains a Buy on Biogen (BIIB)
Wedbush Analyst forecast on BIIB
Laura Chico
Wedbush
Wedbush
$201
Hold
13.34%
Upside
Reiterated
07/15/26
Biogen (BIIB) Receives a Hold from Wedbush
Canaccord Genuity Analyst forecast on BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$245
Buy
38.14%
Upside
Reiterated
07/15/26
Canaccord Genuity Remains a Buy on Biogen (BIIB)
BMO Capital Analyst forecast on BIIB
Evan Seigerman
BMO Capital
BMO Capital
$191.95→$196
Hold
10.52%
Upside
Reiterated
07/15/26
BMO Capital Sticks to Its Hold Rating for Biogen (BIIB)
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
$256
Buy
44.35%
Upside
Reiterated
07/14/26
Biogen: CELIA Phase 2 Data Underpin Continued Confidence in Diranersen; Buy Rating and $256 Price Target Reiterated
William Blair Analyst forecast on BIIB
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/14/26
Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Genmab (GMAB)
H.C. Wainwright Analyst forecast on BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$237
Buy
33.63%
Upside
Reiterated
07/14/26
Biogen: CELIA Trial Data Reinforce Tau Leadership, Support Buy Rating and Unchanged $237 Price Target
Stifel Nicolaus Analyst forecast on BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$214
Buy
20.67%
Upside
Reiterated
07/14/26
Biogen to face questions on safety and dose response, says StifelBiogen to face questions on safety and dose response, says Stifel
RBC Capital Analyst forecast on BIIB
Brian Abrahams
RBC Capital
RBC Capital
$242
Buy
36.45%
Upside
Reiterated
07/14/26
RBC says Biogen detailed Phase 2 results 'leave more questions than answers'RBC says Biogen detailed Phase 2 results 'leave more questions than answers'
Morgan Stanley Analyst forecast on BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
$222
Hold
25.18%
Upside
Reiterated
07/14/26
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (NYSE: HCA) and Biogen (NASDAQ: BIIB)
TD Cowen Analyst forecast on BIIB
Phil Nadeau
TD Cowen
TD Cowen
$215
Buy
21.23%
Upside
Reiterated
07/14/26
Analysts Are Bullish on Top Healthcare Stocks: Atea Pharmaceuticals (AVIR), Biogen (BIIB)
Jefferies Analyst forecast on BIIB
Andrew Tsai
Jefferies
Jefferies
$255
Buy
43.78%
Upside
Reiterated
07/13/26
Early subQ approval a fundamental positive for Biogen, says JefferiesEarly subQ approval a fundamental positive for Biogen, says Jefferies
Citi Analyst forecast on BIIB
Geoff Meacham
Citi
Citi
$200
Hold
12.77%
Upside
Reiterated
07/13/26
IQLIK Approval Seen as Commercial Enhancer, Not Fundamental Shift, as Biogen Neutral Rating and $200 Price Target Remain Unchanged
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on BIIB
Jason Zemansky
Bank of America Securities
Bank of America Securities
$217
Hold
22.36%
Upside
Reiterated
07/17/26
Biogen Maintained at Hold as Analyst Keeps $217 Price Target Amid Alzheimer’s Pipeline Uncertainty
Wells Fargo Analyst forecast on BIIB
Mohit Bansal
Wells Fargo
Wells Fargo
$250
Buy
40.96%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Faeth Therapeutics (NASDAQ: FTH), Oncology Institute (NASDAQ: TOI) and Biogen (NASDAQ: BIIB)
Piper Sandler Analyst forecast on BIIB
David Amsellem
Piper Sandler
Piper Sandler
$225
Buy
26.87%
Upside
Reiterated
07/15/26
Piper Sandler Remains a Buy on Biogen (BIIB)
Wedbush Analyst forecast on BIIB
Laura Chico
Wedbush
Wedbush
$201
Hold
13.34%
Upside
Reiterated
07/15/26
Biogen (BIIB) Receives a Hold from Wedbush
Canaccord Genuity Analyst forecast on BIIB
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$245
Buy
38.14%
Upside
Reiterated
07/15/26
Canaccord Genuity Remains a Buy on Biogen (BIIB)
BMO Capital Analyst forecast on BIIB
Evan Seigerman
BMO Capital
BMO Capital
$191.95→$196
Hold
10.52%
Upside
Reiterated
07/15/26
BMO Capital Sticks to Its Hold Rating for Biogen (BIIB)
Needham Analyst forecast on BIIB
Ami Fadia
Needham
Needham
$256
Buy
44.35%
Upside
Reiterated
07/14/26
Biogen: CELIA Phase 2 Data Underpin Continued Confidence in Diranersen; Buy Rating and $256 Price Target Reiterated
William Blair Analyst forecast on BIIB
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/14/26
Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Genmab (GMAB)
H.C. Wainwright Analyst forecast on BIIB
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$237
Buy
33.63%
Upside
Reiterated
07/14/26
Biogen: CELIA Trial Data Reinforce Tau Leadership, Support Buy Rating and Unchanged $237 Price Target
Stifel Nicolaus Analyst forecast on BIIB
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$214
Buy
20.67%
Upside
Reiterated
07/14/26
Biogen to face questions on safety and dose response, says StifelBiogen to face questions on safety and dose response, says Stifel
RBC Capital Analyst forecast on BIIB
Brian Abrahams
RBC Capital
RBC Capital
$242
Buy
36.45%
Upside
Reiterated
07/14/26
RBC says Biogen detailed Phase 2 results 'leave more questions than answers'RBC says Biogen detailed Phase 2 results 'leave more questions than answers'
Morgan Stanley Analyst forecast on BIIB
Terence Flynn
Morgan Stanley
Morgan Stanley
$222
Hold
25.18%
Upside
Reiterated
07/14/26
Analysts Offer Insights on Healthcare Companies: HCA Healthcare (NYSE: HCA) and Biogen (NASDAQ: BIIB)
TD Cowen Analyst forecast on BIIB
Phil Nadeau
TD Cowen
TD Cowen
$215
Buy
21.23%
Upside
Reiterated
07/14/26
Analysts Are Bullish on Top Healthcare Stocks: Atea Pharmaceuticals (AVIR), Biogen (BIIB)
Jefferies Analyst forecast on BIIB
Andrew Tsai
Jefferies
Jefferies
$255
Buy
43.78%
Upside
Reiterated
07/13/26
Early subQ approval a fundamental positive for Biogen, says JefferiesEarly subQ approval a fundamental positive for Biogen, says Jefferies
Citi Analyst forecast on BIIB
Geoff Meacham
Citi
Citi
$200
Hold
12.77%
Upside
Reiterated
07/13/26
IQLIK Approval Seen as Commercial Enhancer, Not Fundamental Shift, as Biogen Neutral Rating and $200 Price Target Remain Unchanged
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ENOVEnovis
GKOSGlaukos
IMUXImmunic
AVTXAvalo Therapeutics
TARAProtara Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Biogen

3 Months
Salveen RichterGoldman Sachs
Success Rate
15/26 ratings generated profit
58%
Average Return
+1.85%
Copying Salveen Richter's trades and holding each position for 3 Months would result in 57.69% of your transactions generating a profit, with an average return of +1.85% per trade.
1 Year
Myles MinterWilliam Blair
Success Rate
15/22 ratings generated profit
68%
Average Return
+15.46%
Copying Myles Minter's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +15.46% per trade.
2 Years
Myles MinterWilliam Blair
Success Rate
14/22 ratings generated profit
64%
Average Return
+10.28%
Copying Myles Minter's trades and holding each position for 2 Years would result in 63.64% of your transactions generating a profit, with an average return of +10.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BIIB Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
22
31
40
42
41
Hold
38
40
39
32
25
Sell
1
1
1
0
1
Strong Sell
0
0
0
0
0
total
61
72
80
74
67
In the current month, BIIB has received 41 Buy Ratings, 25 Hold Ratings, and 1 Sell Ratings. BIIB average Analyst price target in the past 3 months is 222.67.
Each month's total comprises the sum of three months' worth of ratings.

BIIB Financial Forecast

BIIB Earnings Forecast

Next quarter’s earnings estimate for BIIB is $3.15 with a range of $2.44 to $4.26. The previous quarter’s EPS was $3.57. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s earnings estimate for BIIB is $3.15 with a range of $2.44 to $4.26. The previous quarter’s EPS was $3.57. BIIB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Sales Forecast

Next quarter’s sales forecast for BIIB is $2.46B with a range of $2.22B to $2.66B. The previous quarter’s sales results were $2.40B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.
Next quarter’s sales forecast for BIIB is $2.46B with a range of $2.22B to $2.66B. The previous quarter’s sales results were $2.40B. BIIB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BIIB has Performed in-line its overall industry.

BIIB Stock Forecast FAQ

What is BIIB’s average 12-month price target, according to analysts?
Based on analyst ratings, Biogen Inc.’s 12-month average price target is 222.67.
    What is BIIB’s upside potential, based on the analysts’ average price target?
    Biogen Inc. has 25.55% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BIIB a Buy, Sell or Hold?
          Biogen Inc. has a consensus rating of Moderate Buy which is based on 18 buy ratings, 9 hold ratings and 1 sell ratings.
            What is Biogen Inc.’s price target?
            The average price target for Biogen Inc. is 222.67. This is based on 28 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $260.00 ,the lowest forecast is $157.00. The average price target represents 25.55% Increase from the current price of $177.35.
              What do analysts say about Biogen Inc.?
              Biogen Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 28 Wall Streets Analysts.
                How can I buy shares of BIIB?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.